Novo Nordisk A/S
Explore Novo Nordisk A/S
Core profile pages, annual revenue records, and related research hubs for this company.
Leadership History
4 leaders · Full leadership timeline
Novo Nordisk A/S is a public company listed on NYSE under ticker NVO. Novo Nordisk makes money by developing and selling prescription medicines for diabetes, obesity, rare blood disorders, rare endocrine disorders, and related chronic diseases.
Novo Nordisk makes money by developing and selling prescription medicines for diabetes, obesity, rare blood disorders, rare endocrine disorders, and related chronic diseases.
Chief Executive Officer
Jørgensen executed the strategic pivot toward GLP-1 receptor agonists and obesity therapeutics, overseeing the launch of Ozempic and Wegovy. He has also managed the massive 28.6 billion DKK capital expenditure program to expand global manufacturing capacity and the $16.5 billion Catalent acquisition to secure fill-finish capacity.
Chief Financial Officer
Nielsen managed the financial aspects of the company's explosive growth, including the capital allocation strategy for the massive R&D and manufacturing investments. He played a key role in maintaining the company's strong credit rating and investor confidence during the transition to a pure-play incretin model.
Executive Vice President, Research and Development
Lange leads the company's global R&D organization, overseeing a 34.6 billion DKK annual budget and a pipeline of over 100 clinical projects. He has been instrumental in advancing the semaglutide franchise and expanding the company's presence in cardiovascular outcomes and rare diseases.
Executive Vice President, Commercial
Green is responsible for driving the company's global commercial strategy, including the launch of Wegovy and the navigation of the complex PBM rebate landscape in the US. He has led the expansion of the sales force and the implementation of data-driven commercial execution strategies.
The biggest risk is GLP-1 competition, pricing pressure, supply execution, side-effect scrutiny, and dependence on diabetes and obesity growth.